Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling.
NSGC’s guidelines support equitable access and care to all patients looking to start or grow their families by recommending that “ECS be made available for all individuals considering reproduction and all pregnant reproductive pairs.”
Myriad’s Dale Muzzey, chief scientific officer; Katie Johansen Taber, VP, clinical product research and partnerships; and Gabriel Lazarin, VP of Medical Affairs for Women’s Health, share their perspectives on the impact of the guidelines in the and on Myriad’s channel.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2023 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the impact of the new expanded carrier screening guidelines from NSGC. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Glenn Farrell
(801) 584-1153
Investor Contact:
Matt Scalo
(801) 584-3532
